Biosimilars have been available in Europe for over a decade, and have offered the opportunity to vastly reduce the cost of treatment for a large number of biologic agents. In order to deliver significant savings to the healthcare structure of each individual EU member state, a careful inspection of the market access, pricing, and reimbursement mechanisms in force in each region is paramount.
An in-depth knowledge of what drives payer and physician decision-making on biosimilar use is crucial for biosimilar developers wishing to design market access strategies uniquely tailored to the specific demands in each EU member state.
This analysis summarizes key information on the process of biosimilar approval in Europe, along with associated challenges, and provides highlights on country-specific market access, pricing, and reimbursement mechanisms which drive biosimilar uptake or prove a barrier to their entrance.
Key Topics Covered:
- Executive Summary
- Biosimilar Regulatory Pathway
- Intellectual Property And Legal Issues
- Naming And Labeling
- Substitution And Switching
- Payer Tools To Drive Biosimilar Uptake
- Payer Views And Trends
- Biosimilar Differentiation
For more information about this report visit https://www.researchandmarkets.com/research/g6lc3h/biosimilars?w=4